ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma.

Autor: Dhakal B; Blood and Marrow Transplant and Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, Wisconsin., Shah N; Division of Hematology-Oncology, University of California, San Francisco, California., Kansagra A; Department of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, Texas., Kumar A; Program for Comparative Effectiveness Research, University of South Florida Morsani College of Medicine, Tampa, Florida., Lonial S; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia., Garfall A; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Cowan A; University of Washington, Seattle WA, and Fred Hutch, Seattle, Washington., Poudyal BS; Department of Clinical Hematology and Bone Marrow Transplant, Civil Service Hospital, Kathmandu, Nepal., Costello C; UCSD/Sharp Healthcare Transplant Program, Blood & Marrow Transplant Services, Moore's Cancer Center, San-Diego, California., Gay F; Division of Hematology 1 Clinical Trial Unit, AOU CIttà della salute e della Scienza, University of Torino, Turin, Italy., Cook G; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trial Research, University of Leeds, Leeds, United Kingdom., Quach H; University of Melbourne, St. Vincent's Hospital, Melbourne, Australia., Einsele H; Universitätsklinikum Würzburg, Department of Internal Medicine II, Würzburg, Germany., Schriber J; Cancer Treatment Centers of America, Phoenix, Arizona., Hou J; Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China., Costa L; Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama., Aljurf M; Oncology Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia., Chaudhry M; Department of hematology/Oncology, George Washington University and Cancer Center, Washington, District of Columbia., Beksac M; Department of Hematology, Ankara University, Ankara, Turkey., Prince M; Epworth Healthcare and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia., Mohty M; Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, Sorbonne University, Paris, France., Janakiram M; Division of Myeloma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, California., Callander N; University of Wisconsin Carbone Cancer Center, Madison, Wisconsin., Biran N; Hackensack Meridian Health, John Theurer Cancer Center, Multiple Myeloma Division, Hackensack, New Jersey., Malhotra P; Department of Clinical Hematology & Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India., Otero PR; Clinica Universidad de Navarra, University of Navarra, Pamplona, Spain., Moreau P; Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France., Abonour R; Indiana University School of Medicine, Indianapolis, Indiana., Iftikhar R; Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan., Silberman R; Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon., Mailankody S; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New, York, New York., Gregory T; Colorado Blood Cancer Institute, Sarah Cannon Cancer Network, Denver, Colorado., Lin Y; Mayo Clinic, Rochester, Minnesota., Carpenter P; Division of Clinical Research, Fred Hutchinson Cancer Research Center and Department of Pediatrics, University of Washington, Seattle, Washington., Hamadani M; Blood and Marrow Transplant and Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: mhamadani@mcw.edu., Usmani S; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New, York, New York., Kumar S; Mayo Clinic, Rochester, Minnesota.
Jazyk: angličtina
Zdroj: Transplantation and cellular therapy [Transplant Cell Ther] 2022 Jun; Vol. 28 (6), pp. 284-293. Date of Electronic Publication: 2022 Mar 17.
DOI: 10.1016/j.jtct.2022.03.019
Abstrakt: Over the past decade, therapeutic options in multiple myeloma (MM) have changed dramatically. Given the unprecedented efficacy of novel agents, the role of hematopoietic cell transplantation (HCT) in MM remains under scrutiny. Rapid advances in myeloma immunotherapy including the recent approval of chimeric antigen receptor (CAR) T-cell therapy will impact the MM therapeutic landscape. The American Society for Transplantation and Cellular Therapy convened an expert panel to formulate clinical practice recommendations for role, timing, and sequencing of autologous (auto-HCT), allogeneic (allo-HCT) and CAR T-cell therapy for patients with newly diagnosed (NDMM) and relapsed/refractory MM (RRMM). The RAND-modified Delphi method was used to generate consensus statements. Twenty consensus statements were generated. The panel endorsed continued use of auto-HCT consolidation for patients with NDMM as a standard-of-care option, whereas in the front line allo-HCT and CAR-T were not recommended outside the setting of clinical trial. For patients not undergoing auto-HCT upfront, the panel recommended its use in first relapse. Lenalidomide as a single agent was recommended for maintenance especially for standard risk patients. In the RRMM setting, the panel recommended the use of CAR-T in patients with 4 or more prior lines of therapy. The panel encouraged allo-HCT in RRMM setting only in the context of clinical trial. The panel found RAND-modified Delphi methodology effective in providing a formal framework for developing consensus recommendations for the timing and sequence of cellular therapies for MM.
(Copyright © 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: